ArticleCancer prevention research (Philadelphia, Pa.)2015
Urinary protein biomarkers in the early detection of lung cancer.
Article in Cancer prevention research (Philadelphia, Pa.), 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed.
- In Search of Ideal Solutions for Cancer Diagnosis: From Conventional Methods to Protein Biomarkers in Liquid Biopsy.Proteomes · 2025Review
- Carcinoembryonic antigen-related cell adhesion molecule 1 in cancer: Blessing or curse?European journal of clinical investigation · 2024Review
- Emerging Strategies in Lung Cancer Screening: Blood and Beyond.Clinical chemistry · 2024Review
- Strengthening of CYFRA 21-1 using urine creatinine correction as potential endometriosis biomarker .F1000Research · 2024Article
- Multi-Omic Biomarkers Improve Indeterminate Pulmonary Nodule Malignancy Risk Assessment.Cancers · 2023Article
- The role of carcinoembryonic antigen-related cell adhesion molecule 1 in cancer.Frontiers in immunology · 2023Review
- The Latest Developments in Using Proteomic Biomarkers from Urine and Serum for Non-Invasive Disease Diagnosis and Prognosis.Biomarker insights · 2023Review
- Article
- Urinary Biomarkers for Early Diagnosis of Lung Cancer.Journal of clinical medicine · 2021Article
- Exploring Volatile Organic Compounds in Breath for High-Accuracy Prediction of Lung Cancer.Cancers · 2021Article
- The old CEACAMs find their new role in tumor immunotherapy.Investigational new drugs · 2020Review
- Biomarkers in Early Diagnosis and Early Stage Lung Cancer: The Clinician's Point of View.Journal of clinical medicine · 2020Article
- Emerging non-invasive detection methodologies for lung cancer.Oncology letters · 2020Review
- Exploring potential biomarkers for lung adenocarcinoma using LC-MS/MS metabolomics.The Journal of international medical research · 2020Article
- An Improved Prediction Model for Ovarian Cancer Using Urinary Biomarkers and a Novel Validation Strategy.International journal of molecular sciences · 2019Article
- Volatile organic compounds of biofluids for detecting lung cancer by an electronic nose based on artificial neural network.Journal of applied biomedicine · 2019Article
- Fucosylation genes as circulating biomarkers for lung cancer.Journal of cancer research and clinical oncology · 2018Article
- Whole blood FPR1 mRNA expression predicts both non-small cell and small cell lung cancer.International journal of cancer · 2018Article
- Identification of potential urine proteins and microRNA biomarkers for the diagnosis of pulmonary tuberculosis patients.Emerging microbes & infections · 2018Article
- Urine Proteome Profiling Predicts Lung Cancer from Control Cases and Other Tumors.EBioMedicine · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
The early detection of lung cancer has the potential to greatly impact disease burden through the timely identification and treatment of affected individuals at a manageable stage of development. The insufficient specificity demonstrated by currently used screening and diagnostic techniques has led to intense investigation into biomarkers as diagnostic tools. Urine may represent a noninvasive alternative matrix for diagnostic biomarker development. We performed an analysis of 242 biomarkers in urines obtained from 83 patients with non-small cell lung carcinomas (NSCLC), 74 patients diagnosed with benign pulmonary conditions, and 77 healthy donors. A large number of significant alterations were observed between the NSCLC and control groups. A multivariate analysis identified a three-biomarker panel consisting of IGFBP-1, sIL-1Ra, CEACAM-1, which discriminated NSCLC from healthy controls with a sensitivity/specificity of 84/95 in an initial training set and 72/100 in an independent validation set. This panel performed well among multiple subtypes of NSCLC and early-stage disease but demonstrated only limited efficacy for the discrimination of NSCLC from benign controls and limited specificity for patients with several other cancers and tuberculosis. These findings demonstrate that urine biomarkers may provide screening and diagnostic properties which exceed those reported for serum biomarkers and approach a level necessary for further clinical development.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.